

Electronic Acknowledgement Receipt

EFS ID:	7429729
Application Number:	10821718
International Application Number:	
Confirmation Number:	1509
Title of Invention:	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
First Named Inventor/Applicant Name:	Clyde L. Schultz
Customer Number:	51886
Filer:	Stephen R. Finch/Elizabeth Cullity
Filer Authorized By:	Stephen R. Finch
Attorney Docket Number:	RH01.701US
Receipt Date:	16-APR-2010
Filing Date:	09-APR-2004
Time Stamp:	14:05:14
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	308
Deposit Account	502121
Authorized User	FINCH,STEPHEN R

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (5B/08)	updated_IDS-temp2.pdf	614345 b22a8016c35a8b40e41d8332753c1e13738691	no	6
Warnings:					
Information:					
2	Foreign Reference	WO03092665.pdf	1203420 b63201d13d323c694616c1398b3b051d07606a	no	39
Warnings:					
Information:					
3	NPL Documents	Aiello-Suppression of Retinal Neovascularization in vivo by Inhibition of Vascular Endothelial.pdf	1202450 0b7c716f13f554e0b9184d0328b89f6c0d3d31	no	5
Warnings:					
Information:					
4	NPL Documents	Clark-AVascular Endothelial Growth Factor Antagonist Produced by the Human Placenta.pdf	250904 0b80c1c934973c371d0b105e0d327ce01a0b18af	no	9
Warnings:					
Information:					
5	NPL Documents	Duh-Vascular Endothelial Growth Factor and Diabetes.pdf	371645 d1e55f105d1a015c72096fabb7b7b9447396701	no	8
Warnings:					
Information:					
6	NPL Documents	Flieger-Dramatic Improvement in Hereditary Hemorrhagic Telangiectasia After Treatment.pdf	42706 cc7e8d5c1db6d21bae1559a8c145c3693e9bc6	no	1
Warnings:					
Information:					
7	NPL Documents	Hazzard-Injection of Soluble Vascular Endothelial Growth Factor Receptor 1 into the Preovulatory.pdf	837864 71ee0dbd8949400cc248facc599c432a19f0ca2	no	8
Warnings:					
Information:					
8	NPL Documents	Hetian-A Novel Peptide Isolated from Phage Display Library Inhibits Tumor Growth and Metastasis.pdf	433946 bd40bb8a0cd272b1d643dd1e0a5e007084995cd	no	6

Warnings:					
Information:					
9	NPL Documents	Inoue- Identification of a Vascular Endothelial Growth Factor-VEGF-Antagonist.pdf	306168 d9c0fcd25e0b17eb2884baf56d0ff8cc0b0c2a83	no	5
Warnings:					
Information:					
10	NPL Documents	Kimura- Vascular Endothelial Growth Factor Antagonist Reduces Brain Edema Formation.pdf	406388 d10b0c0a0814a0d6d5c0d85574095b79c956ca092	no	6
Warnings:					
Information:					
11	NPL Documents	Ozaki- Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely.pdf	996852 7d4b0dd19ef3a12b4e9126c02b5d0111d0f700d1	no	11
Warnings:					
Information:					
12	NPL Documents	Pisano-Undersulfated Low-Molecular Weight Glycol Split Heparin as an Antiangiogenic VEGF.pdf	269484 7c3c57E980110118d6113M263e7766470368d2	no	6
Warnings:					
Information:					
13	NPL Documents	Schuch- In Vivo Administration of Vascular Endothelial Growth Factor-VEGF and its Antagonist.pdf	2310962 6d8b0dcd3016618d5c5ab4579644cc52d54a8bc95d8	no	7
Warnings:					
Information:					
14	NPL Documents	Siemeister- An Antagonistic Vascular Endothelial Growth Factor-VEGF Variant Inhibits VEGF.pdf	245096 d96401786d2110633d8940420b15621a76498	no	5
Warnings:					
Information:					
15	NPL Documents	Soker- Inhibition of Vascular Endothelial Growth Factor-VEGF-induced Endothelial Cell.pdf	176362 e0c22d8d6d2781de17ca3507330d1e14885da79	no	7
Warnings:					
Information:					
16	NPL Documents	RH01-704-032009-OA.pdf	3439732 90935d80e013ab2cd8ff0e553d67d62542c4b736	no	27
Warnings:					
Information:					
17	NPL Documents	RH01-702-061009-FOA.pdf	887444 11748400a0c90950851f46d838091c1e018f56d7	no	7

Warnings:					
Information:					
18	NPL Documents	RH01-704-110409-FOA.pdf	1447723 ba216d5b3f4e00f7a7a3d26f124c081c7e0b3	no	13
Warnings:					
Information:					
19	NPL Documents	RH01-702-122409-OA.pdf	1203530 80269d1c5d408413a2e98d57c4d38f6e49308d	no	10
Warnings:					
Information:					
20	NPL Documents	ZHANG-AngiogenicInhibitionMediated byaDNAzymeThatTargetsVascular.pdf	2039680 904911ac297d319d818eb4735f46c2e1813a7	no	7
Warnings:					
Information:					
21	Fee Worksheet (PTO-875)	fee-info.pdf	29856 a008b4c5af2506d124f34b2e4b0c1347dfe0e05	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			18716557		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.					
New Applications Under 35 U.S.C. 111					
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.					
National Stage of an International Application under 35 U.S.C. 371					
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.					
New International Application Filed with the USPTO as a Receiving Office					
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					